Purpose: Trastuzumab deruxtecan (T-DXd) is currently approved for treating metastatic breast cancer (MBC) which is HER2-positive (immunohistochemistry [IHC] score of 3+ or ISH positivity) or HER2-low (IHC score of 1+ or IHC 2+/ISH negative), as well as for HER2-positive gastric cancer, HER2-mutant lung cancer, and HER2 overexpressing solid tumors. Given the increasing utilization of T-DXd, we sought to determine how HER2 receptor status might change following T-DXd therapy.
Design: We retrospectively reviewed patients with MBC who received T-DXd at The University of Texas MD Anderson Cancer Center.
Folia Morphol (Warsz)
January 2025
Background: Diabetic nephropathy (DN), a common complication of type 2 diabetes (T2D), significantly contributes to end-stage kidney disease (ESKD). Despite conventional treatments aimed at slowing disease progression, there is a pressing need for novel therapies. This study evaluates the potential therapeutic impact of adipose tissue derived stromal vascular fraction (SVF) on early diabetic nephrotoxicity in a rat model.
View Article and Find Full Text PDFJ Immunother Precis Oncol
February 2025
Introduction: Uveal melanoma remains a disease with aggressive behavior and poor prognosis despite advances in clinical management. Because monotherapy with immune checkpoint inhibitors has led to limited improvement in response rates, combination with other agents that act on the biological basis of oncogenesis has been proposed as a possible therapeutic strategy.
Methods: We designed a phase 1b trial to test the safety and tolerability of selinexor in combination with immune checkpoint inhibitors in patients with advanced uveal melanoma.
Comp Biochem Physiol A Mol Integr Physiol
January 2025
This work aimed to investigate the response of cholecystokinin (CCK) to starvation and its impact on food intake and the reproductive axis of the tilapia Oreochromis mossambicus. The fish subjected to 21 days of starvation showed a significant decrease in CCK immunoreactivity in the hypothalamus, pituitary gland, and intestine. The administration of injections of 0.
View Article and Find Full Text PDFIn this work, chitosan (Cs) was blended with different concentrations of Origanum majorana extract (OmE) that extracted using ethyl acetate and used for the formation of food packaging films. Based on the utilized volumes of OmE (2.5, 5, and 7.
View Article and Find Full Text PDF